A citation-based method for searching scientific literature

Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari, Maud Ngo-Camus, Rastislav Bahleda, Anas Gazzah, Andrea Varga, Sophie Postel-Vinay, Yohann Loriot, Caroline Even, Ingrid Breuskin, Nathalie Auger, Bastien Job, Thierry De Baere, Frederic Deschamps, Philippe Vielh, Jean-Yves Scoazec, Vladimir Lazar, Catherine Richon, Vincent Ribrag, Eric Deutsch, Eric Angevin, Gilles Vassal, Alexander Eggermont, Fabrice André, Jean-Charles Soria. Cancer Discov 2017
Times Cited: 360







List of co-cited articles
574 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
641
36

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
208
28

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
257
27

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
21

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
O Trédan, Q Wang, D Pissaloux, P Cassier, A de la Fouchardière, J Fayette, F Desseigne, I Ray-Coquard, C de la Fouchardière, D Frappaz,[...]. Ann Oncol 2019
80
23

OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah M Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E Rudolph, Rona Yaeger, Tara Soumerai, Moriah H Nissan,[...]. JCO Precis Oncol 2017
960
18

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, N Lopez-Bigas, C K Y Ng, P L Bedard, G Tortora, J-Y Douillard,[...]. Ann Oncol 2018
203
17

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Daniel D Von Hoff, Joseph J Stephenson, Peter Rosen, David M Loesch, Mitesh J Borad, Stephen Anthony, Gayle Jameson, Susan Brown, Nina Cantafio, Donald A Richards,[...]. J Clin Oncol 2010
432
16

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
258
16

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Tracy L Stockley, Amit M Oza, Hal K Berman, Natasha B Leighl, Jennifer J Knox, Frances A Shepherd, Eric X Chen, Monika K Krzyzanowska, Neesha Dhani, Anthony M Joshua,[...]. Genome Med 2016
148
15

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Clin Oncol 2015
268
14

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
13

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
12

Integrative clinical genomics of metastatic cancer.
Dan R Robinson, Yi-Mi Wu, Robert J Lonigro, Pankaj Vats, Erin Cobain, Jessica Everett, Xuhong Cao, Erica Rabban, Chandan Kumar-Sinha, Victoria Raymond,[...]. Nature 2017
441
11

Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience.
Rouven Hoefflin, Anna-Lena Geißler, Ralph Fritsch, Rainer Claus, Julius Wehrle, Patrick Metzger, Meike Reiser, Leman Mehmed, Lisa Fauth, Dieter Henrik Heiland,[...]. JCO Precis Oncol 2018
23
47

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
Marilyn M Li, Michael Datto, Eric J Duncavage, Shashikant Kulkarni, Neal I Lindeman, Somak Roy, Apostolia M Tsimberidou, Cindy L Vnencak-Jones, Daynna J Wolff, Anas Younes,[...]. J Mol Diagn 2017
773
11

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis J Kuo, Ramez N Eskander, Aaron Goodman, Natalie Galanina,[...]. Nat Commun 2020
84
13

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Jennifer J Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S Falchook,[...]. Cancer Res 2016
157
10

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
10

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
John D Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein,[...]. J Clin Oncol 2018
251
10

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
856
9

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.
Loic Verlingue, David Malka, Adrien Allorant, Christophe Massard, Charles Ferté, Ludovic Lacroix, Etienne Rouleau, Nathalie Auger, Maud Ngo, Claudio Nicotra,[...]. Eur J Cancer 2017
71
12

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
465
9

Genomic characterization of metastatic breast cancers.
François Bertucci, Charlotte K Y Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, Nadine Carbuccia, Jean Charles Soria, Alicia Tran Dien, Yahia Adnani, Maud Kamal,[...]. Nature 2019
291
9

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.
Apostolia-Maria Tsimberidou, David S Hong, Yang Ye, Carrie Cartwright, Jennifer J Wheler, Gerald S Falchook, Aung Naing, Siqing Fu, Sarina Piha-Paul, Filip Janku,[...]. JCO Precis Oncol 2017
91
9

Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen,[...]. Clin Cancer Res 2019
38
23

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.
Apostolia-Maria Tsimberidou, Sijin Wen, David S Hong, Jennifer J Wheler, Gerald S Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape,[...]. Clin Cancer Res 2014
148
8

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Maria Schwaederle, Barbara A Parker, Richard B Schwab, Gregory A Daniels, David E Piccioni, Santosh Kesari, Teresa L Helsten, Lyudmila A Bazhenova, Julio Romero, Paul T Fanta,[...]. Mol Cancer Ther 2016
110
8

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Keith T Flaherty, Robert J Gray, Alice P Chen, Shuli Li, Lisa M McShane, David Patton, Stanley R Hamilton, P Mickey Williams, A John Iafrate, Jeffrey Sklar,[...]. J Clin Oncol 2020
76
10

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
496
8

Community-driven development of a modified progression-free survival ratio for precision oncology.
Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Benedikt Brors, Albrecht Stenzinger, Dirk Jäger, Richard Schlenk,[...]. ESMO Open 2019
10
80

Pan-cancer whole-genome analyses of metastatic solid tumours.
Peter Priestley, Jonathan Baber, Martijn P Lolkema, Neeltje Steeghs, Ewart de Bruijn, Charles Shale, Korneel Duyvesteyn, Susan Haidari, Arne van Hoeck, Wendy Onstenk,[...]. Nature 2019
331
8

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
D L van der Velden, L R Hoes, H van der Wijngaart, J M van Berge Henegouwen, E van Werkhoven, P Roepman, R L Schilsky, W W J de Leng, A D R Huitema, B Nuijen,[...]. Nature 2019
87
9

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter, Andreas Mock, Jennifer Hüllein, Martina Fröhlich, Sebastian Uhrig, Arne Jahn, Andreas Rump,[...]. Cancer Discov 2021
30
26

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010
7

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, Jennifer J Wheler, Gerald S Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra,[...]. Clin Cancer Res 2012
375
7

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
Fabrice André, Thomas Bachelot, Frederic Commo, Mario Campone, Monica Arnedos, Véronique Dieras, Magali Lacroix-Triki, Ludovic Lacroix, Pascale Cohen, David Gentien,[...]. Lancet Oncol 2014
273
7

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
313
7

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
7


Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Pam K Mangat, Susan Halabi, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A Janeway, Philip J Stella, Emile Voest, Kathleen J Yost, Jane Perlmutter,[...]. JCO Precis Oncol 2018
66
10

Molecular profiling for precision cancer therapies.
Eoghan R Malone, Marc Oliva, Peter J B Sabatini, Tracy L Stockley, Lillian L Siu. Genome Med 2020
197
7

Variant classification in precision oncology.
Jonas Leichsenring, Peter Horak, Simon Kreutzfeldt, Christoph Heining, Petros Christopoulos, Anna-Lena Volckmar, Olaf Neumann, Martina Kirchner, Carolin Ploeger, Jan Budczies,[...]. Int J Cancer 2019
34
20

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
7

Precision oncology based on omics data: The NCT Heidelberg experience.
Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils,[...]. Int J Cancer 2017
86
8

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
François Bertucci, Anthony Gonçalves, Arnaud Guille, José Adelaïde, Séverine Garnier, Nadine Carbuccia, Emilien Billon, Pascal Finetti, Patrick Sfumato, Audrey Monneur,[...]. Genome Med 2021
14
50

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng,[...]. Cancer Discov 2017
395
6

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William P Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh,[...]. Br J Cancer 2019
176
6

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.